Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Breast Cancer Research and Treatment Année : 2018

Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens

Matthieu Carton
Jean-Yves Pierga
Marc Debled
  • Fonction : Auteur
  • PersonId : 918984
Anthony Gonçalves
Thierry Petit
Florence Lerebours

Résumé

HER2-negative metastatic breast cancer (MBC) is a common setting in which chemotherapy could be effective even in later lines of treatment. Oral etoposide has demonstrated clinical activity in this setting in small-scale studies, but its efficacy has not been compared to that of other chemotherapy regimens.

Domaines

Cancer
Fichier non déposé

Dates et versions

hal-01926575 , version 1 (19-11-2018)

Identifiants

Citer

Luc Cabel, Matthieu Carton, Bianca Cheaib, Jean-Yves Pierga, Florence Dalenc, et al.. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens. Breast Cancer Research and Treatment, 2018, ⟨10.1007/s10549-018-5017-2⟩. ⟨hal-01926575⟩
117 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More